360 related articles for article (PubMed ID: 33670397)
1. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.
Verhoeven Y; Quatannens D; Trinh XB; Wouters A; Smits ELJ; Lardon F; De Waele J; van Dam PA
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670397
[TBL] [Abstract][Full Text] [Related]
2. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
Bose CK
Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
[TBL] [Abstract][Full Text] [Related]
4. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
Dyer BA; Zamarin D; Eskandar RN; Mayadev JM
J Natl Compr Canc Netw; 2019 Jan; 17(1):91-97. PubMed ID: 30659133
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab in recurrent advanced cervical squamous carcinoma.
Martínez P; Del Campo JM
Immunotherapy; 2017 May; 9(6):467-470. PubMed ID: 28399693
[TBL] [Abstract][Full Text] [Related]
6. Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.
Cohen AC; Roane BM; Leath CA
Drugs; 2020 Feb; 80(3):217-227. PubMed ID: 31939072
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab for advanced cervical cancer: safety and efficacy.
De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
[No Abstract] [Full Text] [Related]
8. Pembrolizumab for the treatment of cervical cancer.
Marret G; Borcoman E; Le Tourneau C
Expert Opin Biol Ther; 2019 Sep; 19(9):871-877. PubMed ID: 31322926
[No Abstract] [Full Text] [Related]
9. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
10. IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER.
Jiménez-Lima R; Arango-Bravo E; Galicia-Carmona T; Lino-Silva LS; Trejo-Durán GE; Alvarado-Silva C; Castañeda-Renderos OH; Vanoye-Carlo EG; Torre CF; Dueñas-González A; Cetina-Pérez L
Rev Invest Clin; 2020; 72(4):231-238. PubMed ID: 33064705
[TBL] [Abstract][Full Text] [Related]
11. PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.
Tuyaerts S; Van Nuffel AMT; Naert E; Van Dam PA; Vuylsteke P; De Caluwé A; Aspeslagh S; Dirix P; Lippens L; De Jaeghere E; Amant F; Vandecasteele K; Denys H
BMC Cancer; 2019 May; 19(1):506. PubMed ID: 31138229
[TBL] [Abstract][Full Text] [Related]
12. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy: Who Is Eligible?
Wang D; Gilbert J; Kim YJ
Otolaryngol Clin North Am; 2017 Aug; 50(4):867-874. PubMed ID: 28755708
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
16. Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer.
Ge Y; Zhang Y; Zhao KN; Zhu H
Drug Des Devel Ther; 2022; 16():3055-3070. PubMed ID: 36110399
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Cervical Cancer.
Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
19. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
20. Advances in immunotherapy for cervical cancer.
Wendel Naumann R; Leath CA
Curr Opin Oncol; 2020 Sep; 32(5):481-487. PubMed ID: 32740092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
